Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

By afschroeder • September 9, 2025

Falchi L, Sureda A, Leppä S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909. Epub ahead of print. PMID: 40920572.

Tags: Hematology/Oncology, Publications

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]

Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis

Brauer ER, Choi KR, Petersen L, Ganz PA, St John MA, Wong DJ, Martin EJ. Social wellbeing, loneliness, and symptom burden in head and neck[...]

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]